Company profile

Beijing Biotech

Privately held: no public share price

Assets

(5 total)
5Total Assets
0Approved
0Phase 3 / Filed
5Phase 1–2 / Early
3Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Beijing Biotech anti-CD19 CAR-T
Phase 2
CD19
Systemic Lupus Erythematosus
Beijing Biotech BCMA/CD19 dual-target CAR-T
Phase 2
BCMA / CD19Cell therapy
Multiple Myeloma
Beijing Biotech BCMA/CD38 dual-target CAR-T
Phase 2
BCMA, CD38 (dual-target)Cell therapy
Multiple Myeloma
Beijing Biotech BCMA/GPRC5D dual-target CAR-T
Phase 2
BCMA / GPRC5DCell therapy
Multiple Myeloma
Dual-target Car-nk Cells
Phase 2
Dual-antigen combinations: MSLN+EGFR, MSLN+HER2/ERBB2Cell therapy
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.